Welcome to our dedicated page for Tango Therapeutics news (Ticker: TNGX), a resource for investors and traders seeking the latest updates and insights on Tango Therapeutics stock.
Tango Therapeutics, Inc. (TNGX) is a clinical-stage biotechnology company pioneering precision oncology solutions through innovative target discovery and therapeutic development. This page provides authorized updates on their research programs, clinical trials, and strategic initiatives in cancer treatment innovation.
Investors and researchers will find verified information about TNGX's pipeline progress, including PRMT5 inhibitor developments for CNS/non-CNS cancers and discontinued programs like TNG348. All content undergoes strict verification to ensure accuracy in reporting scientific milestones and regulatory updates.
Key coverage areas include clinical trial phases, research collaborations, peer-reviewed study publications, and corporate developments. The resource is particularly valuable for tracking therapies addressing tumor suppressor gene restoration and immune evasion mechanisms.
Bookmark this page for real-time updates on Tango Therapeutics' work in CRISPR-enabled drug discovery and their mission to transform cancer treatment paradigms through precision medicine approaches.
Tango Therapeutics (Nasdaq: TNGX) priced an underwritten offering and a concurrent PIPE to raise approximately $225 million in gross proceeds. The offering includes 21,023,337 shares of common stock and pre-funded warrants to purchase up to 3,226,458 shares at a per-share price of $8.66 (pre-funded warrant price $8.659). Gross proceeds from the offering are expected to be about $210 million; the PIPE is selling 1,732,101 shares for about $15 million. The transactions are expected to close on or about October 24, 2025, subject to customary conditions.
Tango Therapeutics (NASDAQ: TNGX) reported positive Phase 1/2 data for vopimetostat (TNG462) in MTAP-deleted cancers dated October 23, 2025. Across 94 evaluable patients, the overall ORR is 27%, disease control rate 78%, and median PFS 6.4 months. In 2L MTAP-del pancreatic cancer (n=39 at active doses) ORR 25% and mPFS 7.2 months; company plans a ~300-patient global randomized pivotal trial in 2026 at the FDA-aligned dose 250 mg QD. A histology-agnostic cohort (excluding pancreatic, lung, sarcoma) showed ORR 49% and mPFS 9.1 months. Safety at 250 mg QD was generally tolerable; most common TRAEs were nausea, anemia, fatigue, dysgeusia, thrombocytopenia.
Tango Therapeutics (NASDAQ: TNGX) will present three posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025 in National Harbor, MD, Nov 5–9, 2025.
Presentations include the first clinical data for TNG260, a first‑in‑class CoREST inhibitor being evaluated in the dose‑expansion phase of a Phase 1/2 trial in combination with pembrolizumab. The trial is enrolling patients with STK11‑mutant/RAS wild‑type lung cancer (about ~10% of lung adenocarcinoma).
All three posters are scheduled for Friday, November 7, 2025 (9:00am–7:00pm EDT). Key abstracts: #561 (clinical Phase 1/2; presenter Salman R. Punekar, M.D.), #681 (TNG260 sensitization; presenter Leanne Ahronian, Ph.D.), and #1225 (MGAT1 inhibition overcoming STK11 immune evasion).
Tango Therapeutics (NASDAQ:TNGX) announced its upcoming participation in the 2025 Cantor Global Healthcare Conference. The company's President and CEO, Barbara Weber, M.D., will participate in a fireside chat on September 3, 2025, from 2:45-3:15 PM ET.
Investors can access the live webcast through the "Events & Presentations" section on the company's investor relations website. The presentation recording will remain available for 90 days following the event.
Tango Therapeutics (NASDAQ:TNGX) reported Q2 2025 financial results and pipeline updates. The company achieved key milestones in its clinical programs, including first patient dosing in two trials: a combination trial of TNG462 with Revolution Medicines' RAS(ON) inhibitors and a Phase 1/2 trial of TNG456 for glioblastoma.
Financial highlights include $180.8 million in cash reserves expected to fund operations into Q1 2027. Q2 2025 showed revenue of $3.2 million, down from $7.8 million in Q2 2024, and a net loss of $38.9 million ($0.35 per share). The company's collaboration with Gilead will conclude its research portion early, resulting in $53.8 million revenue recognition in Q3 2025.
Tango Therapeutics (NASDAQ: TNGX) announced it will release its second quarter 2025 financial results on Tuesday, August 5, 2025, before U.S. markets open. The company stated it will not host a conference call to discuss the results.
Tango Therapeutics (NASDAQ: TNGX) has initiated dosing in a Phase 1/2 trial combining its TNG462 with Revolution Medicines' daraxonrasib or zoldonrasib in patients with MTAP-deleted and RAS mutant metastatic pancreatic or lung cancer.
The study aims to evaluate safety, pharmacokinetics, pharmacodynamics, and antitumor activity. TNG462, a MTA-cooperative PRMT5 inhibitor, is also being studied as monotherapy with data expected in H2 2025. The monotherapy results will inform a registrational trial in pancreatic cancer and advance the lung cancer development plan.
Tango Therapeutics (NASDAQ: TNGX) announced that its President and CEO, Barbara Weber, M.D., will participate in a fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference. The presentation is scheduled for June 10 at 3:20-3:55 PM ET. Investors can access the live webcast through the "Events & Presentations" section on the company's website, and a replay will be available for 90 days following the event.
Tango Therapeutics (NASDAQ: TNGX) has initiated dosing in its Phase 1/2 clinical trial of TNG456, a next-generation, brain-penetrant, MTA-cooperative PRMT5 inhibitor. The trial focuses on patients with MTAP-deleted solid tumors, particularly glioblastoma (GBM). The study (NCT06810544) will evaluate TNG456's safety, pharmacokinetics, pharmacodynamics, and antitumor activity both as monotherapy and in combination with abemaciclib.
The trial's significance is highlighted by the current poor prognosis for GBM patients, who face a five-year survival rate below 10%. Notably, 45% of GBM cases are MTAP-deleted, presenting a substantial potential patient population. Preclinical studies have shown promising results regarding TNG456's potency, MTAP-selectivity, and brain exposure, suggesting potential efficacy in GBM treatment.
FAQ
What is the current stock price of Tango Therapeutics (TNGX)?
What is the market cap of Tango Therapeutics (TNGX)?
